Research Theme

The Yeh Lab focuses on the creation of engineered biologics such as antibodies, proteins, peptidomimetics and Natural Product (NP)-like macrocycles as therapeutics and diagnostics. To this end, we employ molecular engineering and chemical biology approaches to develop molecules acting on signal transduction machineries in order to abrogate pathological cell signaling. The ultimate goal is to develop next-generation therapeutics and diagnostics for better disease treatments. Currently our major focus is  in the area of oncology and immuno-oncology. We also have close collaborations with clinical centers and industry organizations to move our molecules from bench to patients.

About the Lab  

Basing on the bimolecular engineering expertise and academic-industrial experience of Dr. Johannes Yeh, the Yeh Lab @ CSHL was established in 2016. Prior to the inception of the Yeh Lab. Dr. Yeh has extensive experience in developing biologics and NP-like molecules for therapeutics and diagnosis. His past research has contributed to the foundation of start-up companies,  academic-industry technology transfer licenses, and FDA approved drugs or drugs in clinical trials. Fueled by the rich experience and entrepreneurship spirit, the Yeh Lab is fully engaged in translation research to bring innovation impacts to humanity.

  • Targeted Protein Degradation

Illustrator: Phoebe Fechtmeyer

  • Targeting Tumor Microenvironment – 

We recently developed therapeutic mAb inhibitors that block dormant cancer cells from reawakening!!! See full story  in <Science>.

  • Chemical Biology & Drug Discovery – converting the undruggables to druggables

Structure-guided and Directed Evolution-empowered Drug Discovery